Estimated launch time of brigatinib/brigatinib in China

The original drug Brigatinib/Brigatinib is sold in China. Brigatinib tablets will be available for sale in China in 2022 for the treatment of certain types of metastatic (cancer that has spread) non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK) gene abnormalities. After being launched in China, brigatinib has also entered the category of Class B medical insurance, and patients who meet the indications can use medical insurance for reimbursement.

Brigatinib, formerly known as AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It exhibits selectivity for mutant forms of EGFR compared with wild type. It also showed selectivity for nine different crizotinib-resistant mutants of the EML4-ALK fusion gene, which plays a key role in the transformation of susceptible lung parenchyma. Therefore brigatinib is used in patients who have been treated with crizotinib but whose condition worsens or the drug stops working. Brigatinib is an antineoplastic (cancer) drug. It interferes with the growth of cancer cells, which are eventually eliminated by the body.

The drug brigatinib is only available with a doctor's prescription. Patients must weigh the risks and benefits of taking the drug before using it. Although Bugatinib is well tolerated, the drug can also cause some side effects, such as nausea, diarrhea, fatigue, cough, headache, rash, vomiting, difficulty breathing, high blood pressure, etc.

Currently, there are various pharmaceutical specifications available on the domestic market, including 30 mg 14 tablets in 2 plates, 90 mg 7 tablets or 7 tablets in 4 plates, and 180 mg 7 tablets in 4 plates. However, it should be noted that the price of this medicine is relatively high, and each box may cost close to 10,000 yuan.